Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gruenberger

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2006
Bevacizumab is active in malignant effusionO Pichelmayer, B Gruenberger, C Zielinski, et al.
Current Medical Research and Opinion|December 17, 2013
Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in GermanyR Göke, J B Gruenberger, G Bader, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2010
Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimenMartin Czejka, J Schueller, A Farkouh, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 15, 2008
Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastasesS Kandutsch, M Klinger, S Hacker, et al.
Diabetes, Obesity & Metabolism|August 7, 2012
Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysisW Rathmann, K Kostev, J B Gruenberger, et al.
The British Journal of Surgery|July 11, 2009
Lymph node ratio after curative surgery for intrahepatic cholangiocarcinomaD Tamandl, K Kaczirek, B Gruenberger, et al.
The British Journal of Ophthalmology|May 2, 2009
Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-StudyK E Schmid-Kubista, I Krebs, B Gruenberger, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 14, 2015
Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastasesS Stremitzer, J Stift, J Singh, et al.
The British Journal of Surgery|October 3, 2012
KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumabS Stremitzer, J Stift, B Gruenberger, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 10, 2009
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastasesM Klinger, S Eipeldauer, S Hacker, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2006
Bevacizumab is active in malignant effusionO Pichelmayer, B Gruenberger, C Zielinski, et al.
Current Medical Research and Opinion|December 17, 2013
Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in GermanyR Göke, J B Gruenberger, G Bader, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2010
Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimenMartin Czejka, J Schueller, A Farkouh, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 15, 2008
Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastasesS Kandutsch, M Klinger, S Hacker, et al.
Diabetes, Obesity & Metabolism|August 7, 2012
Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysisW Rathmann, K Kostev, J B Gruenberger, et al.
The British Journal of Surgery|July 11, 2009
Lymph node ratio after curative surgery for intrahepatic cholangiocarcinomaD Tamandl, K Kaczirek, B Gruenberger, et al.
The British Journal of Ophthalmology|May 2, 2009
Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-StudyK E Schmid-Kubista, I Krebs, B Gruenberger, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 14, 2015
Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastasesS Stremitzer, J Stift, J Singh, et al.
The British Journal of Surgery|October 3, 2012
KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumabS Stremitzer, J Stift, B Gruenberger, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 10, 2009
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastasesM Klinger, S Eipeldauer, S Hacker, et al.
Pageof 2